Home » Core Components » LPCAT3

LPCAT3

Last updated: December 24, 2025 | By Leif

The Other Half of the Lipid Vulnerability Equation

When researchers discovered that ACSL4 determines ferroptosis sensitivity by activating polyunsaturated fatty acids (PUFAs), a critical question remained: how do these activated fatty acids actually get incorporated into membrane phospholipids where they become vulnerable to peroxidation?

The answer came with the discovery of LPCAT3 (Lysophosphatidylcholine Acyltransferase 3), an enzyme that works in tandem with ACSL4 to build PUFA-containing phospholipids. Together, ACSL4 and LPCAT3 form a metabolic partnership that determines membrane lipid composition and, consequently, ferroptosis susceptibility.

While ACSL4 prepares the PUFA “building blocks” by making PUFA-CoA, LPCAT3 is the enzyme that actually installs these PUFAs into phospholipids. Without LPCAT3, even cells with abundant ACSL4 and PUFA-CoA cannot build the lipid substrates necessary for ferroptosis. This makes LPCAT3 an equally critical determinant of ferroptosis sensitivity.

What is LPCAT3?

LPCAT3 (Lysophosphatidylcholine Acyltransferase 3) is an enzyme that catalyzes the acylation of lysophospholipids—the incorporation of fatty acids into membrane phospholipids. Specifically, LPCAT3 adds fatty acids to the sn-2 position of lysophospholipids, converting them into complete phospholipids.

The LPCAT Family:

LPCAT3 belongs to a family of lysophosphatidylcholine acyltransferases:

LPCAT1: Abundant in lungs, important for surfactant production
LPCAT2: Widely expressed, general phospholipid remodeling
LPCAT3: Unique preference for PUFA incorporation
LPCAT4: Less well characterized

Each family member has different tissue distribution, substrate preferences, and biological roles. LPCAT3’s distinguishing feature is its strong preference for incorporating polyunsaturated fatty acids—the same fatty acids that make membranes vulnerable to ferroptosis.

The Discovery of LPCAT3’s Role in Ferroptosis

LPCAT3’s connection to ferroptosis emerged from the same genetic screens that identified ACSL4:

2016-2017: Parallel Discovery

Multiple research groups conducting CRISPR screens to identify ferroptosis regulators independently discovered LPCAT3:

Kimberly Pratt’s group found that cells lacking LPCAT3 were highly resistant to ferroptosis, similar to ACSL4-deficient cells
Scott Dixon’s group identified LPCAT3 in screens for genes whose loss protects against RSL3 and erastin
Lipidomics studies revealed that LPCAT3-deficient cells had dramatically different membrane phospholipid composition—specifically, much lower PUFA content

The pattern was striking: just like ACSL4, LPCAT3 loss made cells ferroptosis-resistant without affecting their response to other forms of cell death (apoptosis, necroptosis). This suggested LPCAT3 played a specific role in creating the lipid substrates for ferroptosis.

How LPCAT3 Works: The Molecular Mechanism

LPCAT3 catalyzes a key step in phospholipid biosynthesis and remodeling:

The Reaction:

Lysophospholipid + Acyl-CoA → Phospholipid + CoA

More specifically for ferroptosis-relevant substrates:

Lysophosphatidylcholine (LPC) + PUFA-CoA → Phosphatidylcholine (PC) + CoA Lysophosphatidylethanolamine (LPE) + PUFA-CoA → Phosphatidylethanolamine (PE) + CoA

Step-by-Step:

Substrate Recognition: LPCAT3 recognizes lysophospholipids—phospholipids that are missing the fatty acid at the sn-2 position
PUFA-CoA Binding: LPCAT3 has a preference for PUFA-CoA molecules (the products of ACSL4’s activity), particularly those containing arachidonic acid (AA) or adrenic acid (AdA)
Acyl Transfer: LPCAT3 transfers the PUFA from CoA to the sn-2 position of the lysophospholipid, creating a complete phospholipid with a PUFA at sn-2
Product Release: The resulting phospholipid (now containing a PUFA) is released and incorporates into cellular membranes, while free CoA is released

The Critical sn-2 Position:

The sn-2 position of phospholipids is particularly important for ferroptosis:

This position is where PUFAs are typically found in natural membranes
Fatty acids at sn-2 are especially accessible to oxidation
Lipid peroxidation predominantly affects PUFA-containing phospholipids with the PUFA at sn-2

By specifically installing PUFAs at this vulnerable position, LPCAT3 creates the exact lipid species that are susceptible to ferroptotic lipid peroxidation.

The ACSL4-LPCAT3 Partnership

ACSL4 and LPCAT3 form an essential metabolic partnership—a two-enzyme system that controls PUFA incorporation into membranes:

Division of Labor:

ACSL4’s Role:

Activates free PUFAs by attaching them to CoA
Makes PUFA-CoA (the “activated” form)
Prepares fatty acids for membrane incorporation

LPCAT3’s Role:

Takes PUFA-CoA and installs it into phospholipids
Specifically targets the sn-2 position
Completes the membrane integration process

Sequential Action:

Free PUFA (e.g., arachidonic acid) enters the cell
ACSL4 converts PUFA → PUFA-CoA
LPCAT3 uses PUFA-CoA to acylate lysophospholipids
Resulting PUFA-containing phospholipids integrate into membranes
These PUFA-rich membranes become vulnerable to lipid peroxidation
When GPX4 fails, ferroptosis occurs

Mutual Dependency:

Both enzymes are necessary for maximum ferroptosis sensitivity:

ACSL4 without LPCAT3: PUFA-CoA is made but can’t efficiently get into membrane phospholipids
LPCAT3 without ACSL4: The enzyme works, but lacks sufficient PUFA-CoA substrate
Both present: Efficient PUFA incorporation → high ferroptosis sensitivity
Either absent: Low PUFA incorporation → ferroptosis resistance

This partnership explains why genetic screens identified both enzymes independently—losing either one provides protection.

LPCAT3 Substrate Specificity

LPCAT3’s preference for certain substrates determines its role in ferroptosis:

Fatty Acid Preferences:

Strongly Preferred:

Arachidonic acid (AA, C20:4 n-6): The most common PUFA in many cell membranes
Adrenic acid (AdA, C22:4 n-6): Another highly unsaturated fatty acid
Other long-chain PUFAs

Less Preferred:

Monounsaturated fatty acids (MUFAs) like oleic acid
Saturated fatty acids

Phospholipid Head Group Preferences:

LPCAT3 can acylate different types of lysophospholipids:

Lysophosphatidylcholine (LPC) → Phosphatidylcholine (PC)
Lysophosphatidylethanolamine (LPE) → Phosphatidylethanolamine (PE)

Both PC and PE species containing PUFAs at sn-2 are relevant ferroptosis substrates, with PE-containing species being particularly important.

The Ferroptosis-Relevant Products:

Lipidomics studies have identified specific phospholipid species that accumulate when ACSL4 and LPCAT3 are active:

PC(AA): Phosphatidylcholine with arachidonic acid at sn-2
PC(AdA): Phosphatidylcholine with adrenic acid at sn-2
PE(AA): Phosphatidylethanolamine with arachidonic acid at sn-2
PE(AdA): Phosphatidylethanolamine with adrenic acid at sn-2

These exact lipid species become oxidized during ferroptosis and are reduced by GPX4 in healthy cells.

Membrane Remodeling: The Lands Cycle

LPCAT3 participates in the Lands cycle—a phospholipid remodeling pathway that allows cells to customize their membrane composition:

The Lands Cycle Process:

Deacylation: Phospholipase A2 (PLA2) removes the fatty acid from the sn-2 position of a phospholipid, creating a lysophospholipid
Reacylation: LPCAT3 (or other LPCAT enzymes) adds a new fatty acid to the sn-2 position, completing the phospholipid

Why This Matters:

The Lands cycle allows cells to:

Adjust membrane fluidity by changing fatty acid composition
Respond to dietary fatty acid availability
Regulate signaling lipid production
Control ferroptosis susceptibility by modulating PUFA content

Through repeated cycles of deacylation and LPCAT3-mediated reacylation with PUFAs, cells can increase their membrane PUFA content and ferroptosis vulnerability.

LPCAT3 Tissue Expression and Localization

Cellular Localization:

LPCAT3 localizes to the endoplasmic reticulum (ER)—the primary site of phospholipid biosynthesis in cells. This ER localization positions LPCAT3 exactly where new phospholipids are made and existing ones are remodeled.

Tissue Expression Patterns:

LPCAT3 expression varies across tissues:

High Expression:

Liver: High metabolic activity and lipid turnover
Small intestine: High membrane synthesis for nutrient absorption
Adipose tissue: Lipid storage and metabolism
Some cancer cell lines: Variable depending on tumor type

Moderate/Low Expression:

Many other tissues show lower baseline expression
Expression can be induced by various stimuli

Cell Type Variation:

Just like ACSL4, LPCAT3 expression varies among cell types, creating heterogeneous ferroptosis sensitivity:

Cells with high LPCAT3 + high ACSL4 = very sensitive to ferroptosis
Cells lacking either enzyme = resistant to ferroptosis
This heterogeneity explains why some tumors respond to ferroptosis induction while others don’t

LPCAT3 in Cancer

LPCAT3’s role in determining ferroptosis sensitivity makes it highly relevant to cancer biology:

Ferroptosis-Sensitive Cancers:

Tumors expressing both ACSL4 and LPCAT3 are particularly vulnerable to ferroptosis induction:

Renal cell carcinoma: Often shows high expression of both enzymes
Triple-negative breast cancer: Some subtypes express both
Certain lymphomas: High ACSL4/LPCAT3 expression
Pancreatic cancer: Variable but often positive

These cancers may be excellent candidates for ferroptosis-inducing therapies.

Resistance Through LPCAT3 Loss:

Cancer cells can evade ferroptosis by downregulating LPCAT3:

Reduced LPCAT3 → less PUFA incorporation → ferroptosis resistance
Some tumors naturally lack LPCAT3
Acquired resistance can involve LPCAT3 suppression

Biomarker Potential:

LPCAT3 expression (along with ACSL4) could serve as a predictive biomarker:

Testing tumors for ACSL4 + LPCAT3 expression
High expression → likely to respond to ferroptosis inducers
Low expression → may need alternative strategies
Guides patient selection for ferroptosis-based therapies

Therapeutic Resistance:

Understanding LPCAT3’s role helps explain therapy resistance:

Why some cancers don’t respond to GPX4 inhibitors (lack ACSL4/LPCAT3)
How resistance develops (downregulation of lipid vulnerability pathway)
Potential combination strategies (preventing LPCAT3 downregulation)

LPCAT3 Beyond Ferroptosis

While LPCAT3’s role in ferroptosis is now well-established, it serves other cellular functions:

Phospholipid Homeostasis:

Maintains proper membrane phospholipid composition
Regulates membrane fluidity
Ensures appropriate lipid diversity

Eicosanoid Precursor Supply:

By incorporating arachidonic acid into phospholipids, LPCAT3 creates a reservoir for inflammatory mediator production
PLA2 can release AA from phospholipids for eicosanoid (prostaglandin, leukotriene) synthesis

Metabolic Regulation:

LPCAT3 influences cellular lipid metabolism
May affect energy storage and utilization
Links fatty acid availability to membrane composition

Development and Physiology:

LPCAT3 knockout mice show developmental defects
Essential for normal tissue function
Particularly important in liver and intestinal function

Regulation of LPCAT3

Understanding what controls LPCAT3 expression and activity is an active research area:

Transcriptional Regulation:

Metabolic transcription factors may influence LPCAT3 expression
Stress responses could modulate levels
Tissue-specific factors maintain expression patterns

Metabolic Control:

Substrate availability (lysophospholipids and acyl-CoA) affects activity
Dietary fatty acid composition influences what gets incorporated
Cellular energy status may impact enzyme function

Post-Translational Regulation:

Potential phosphorylation or other modifications
Protein stability and degradation pathways
Mechanisms still being elucidated

Coordination with ACSL4:

Some evidence suggests coordinated regulation
Cells may maintain balanced expression of both enzymes
Ensures efficient PUFA incorporation pipeline

LPCAT3 in Other Diseases

Liver Disease:

LPCAT3’s high expression in liver makes it relevant to hepatic diseases:

NAFLD/NASH: Altered lipid composition contributes to disease
Hepatotoxicity: LPCAT3 may influence drug-induced liver injury
Liver regeneration: LPCAT3 supports membrane biosynthesis during recovery

Metabolic Disorders:

Obesity: LPCAT3 in adipose tissue affects lipid storage
Insulin resistance: Membrane lipid composition influences insulin signaling
Dyslipidemia: LPCAT3 contributes to phospholipid profiles

Inflammatory Conditions:

By regulating AA-containing phospholipids, LPCAT3 influences inflammatory mediator availability
May modulate immune cell function
Potential role in chronic inflammatory diseases

Experimental Approaches and Tools

Studying LPCAT3:

Genetic Manipulation:

CRISPR knockout: Eliminate LPCAT3 to create ferroptosis-resistant cells
Overexpression: Increase LPCAT3 to enhance ferroptosis sensitivity
Knockdown: siRNA/shRNA to reduce expression
Conditional knockout: Tissue-specific or inducible deletion in animals

Lipidomics:

Mass spectrometry: Identify and quantify specific phospholipid species
Comparison: LPCAT3+ vs. LPCAT3- cells show dramatic lipid composition differences
Time course: Track PUFA incorporation during ferroptosis

Functional Assays:

Ferroptosis sensitivity: Measure cell death in response to erastin, RSL3
Lipid peroxidation: C11-BODIPY or other probes
Rescue experiments: Adding/removing LPCAT3 changes ferroptosis response

Measurement:

Western blotting: Protein expression levels
qPCR: mRNA expression
Enzyme activity assays: Acyltransferase activity measurement

No Specific Inhibitors (Yet):

Unlike ACSL4 (which has some inhibitors) or GPX4 (RSL3, ML162), there are currently no well-characterized, selective LPCAT3 inhibitors available for research or therapy. This represents a gap and an opportunity:

Developing LPCAT3 inhibitors could provide new ferroptosis research tools
LPCAT3 inhibition might protect against ferroptosis in disease
Could be useful for studying LPCAT3’s non-ferroptosis functions

LPCAT3 vs. Other LPCAT Family Members

What makes LPCAT3 special compared to other LPCAT enzymes?

LPCAT1:

Abundant in lung, crucial for surfactant
Preference for saturated fatty acids
Doesn’t significantly contribute to ferroptosis sensitivity

LPCAT2:

Widely expressed, general remodeling enzyme
Broader substrate specificity
Minor role in ferroptosis compared to LPCAT3

LPCAT3:

Unique PUFA preference distinguishes it
Specifically creates ferroptosis-vulnerable lipids
This substrate selectivity is the key difference

LPCAT4:

Less characterized
Role in ferroptosis unclear
May have some overlapping functions

The specificity matters: only LPCAT3 efficiently incorporates the highly unsaturated fatty acids that create ferroptosis vulnerability.

Dietary Fatty Acids and LPCAT3

An interesting implication of LPCAT3’s role: dietary fatty acid composition could influence ferroptosis susceptibility.

High PUFA Diet:

More arachidonic acid, EPA, DHA available
ACSL4-LPCAT3 pathway incorporates them into membranes
Potentially increased ferroptosis sensitivity

High MUFA Diet (e.g., Mediterranean diet):

More oleic acid, less AA/EPA/DHA
Even with active ACSL4-LPCAT3, less vulnerable lipids created
Potentially decreased ferroptosis sensitivity

Clinical Implications:

Could diet modulate disease risk related to ferroptosis?
Might dietary intervention complement ferroptosis-based therapies?
Could fatty acid supplementation protect against ferroptotic damage?

Important Caveat: The relationship between dietary fats and ferroptosis in humans is complex and not yet well-established. While cell culture and animal studies show effects, translating to human disease requires more research.

Therapeutic Implications

Cancer Treatment (Exploit LPCAT3):

Patient Selection:

Test tumors for ACSL4 and LPCAT3 expression
High expression → good candidates for ferroptosis induction
Low expression → may need alternative approaches

Combination Strategies:

Prevent compensatory downregulation of LPCAT3
Combine with GPX4, FSP1, or GCH1 inhibition
Enhance PUFA availability to maximize substrate

Resistance Monitoring:

Track LPCAT3 expression during therapy
Detect emerging resistance via LPCAT3 loss
Adjust treatment accordingly

Neuroprotection (Inhibit LPCAT3):

Rationale:

Reducing PUFA incorporation could protect neurons
Lower ferroptosis vulnerability in stroke, neurodegeneration
Complement GPX4-enhancing strategies

Challenges:

Need brain-penetrant LPCAT3 inhibitors (don’t exist yet)
Potential off-target effects on normal phospholipid metabolism
Uncertain long-term consequences

Metabolic Disease:

LPCAT3 manipulation might influence liver disease progression
Could affect inflammatory responses
Potential for metabolic disorder treatment

Current Research Questions

Many aspects of LPCAT3 in ferroptosis remain under investigation:

How is LPCAT3 expression coordinated with ACSL4?
What transcription factors control LPCAT3 in different contexts?
Can we develop selective LPCAT3 inhibitors?
Does LPCAT3 have other ferroptosis-independent roles in disease?
How do cells decide which fatty acids LPCAT3 incorporates?
Can dietary interventions meaningfully modulate LPCAT3-mediated ferroptosis sensitivity?
What determines LPCAT3 expression differences between cell types?

Key Takeaways

LPCAT3 is the essential partner to ACSL4 in determining ferroptosis vulnerability:

It incorporates PUFAs into the sn-2 position of phospholipids
Works sequentially with ACSL4 to build ferroptosis-vulnerable lipids
Both enzymes must be present for maximum ferroptosis sensitivity
Loss of either ACSL4 or LPCAT3 provides ferroptosis resistance
Expression patterns help predict which cells/tumors are ferroptosis-sensitive
Represents a potential therapeutic target (though inhibitors don’t yet exist)
Links cellular lipid metabolism directly to cell death susceptibility
Demonstrates how routine metabolic enzymes can determine cell fate

LPCAT3 exemplifies how ferroptosis research has revealed unexpected connections between basic metabolism and cell death. An enzyme long studied for its role in phospholipid remodeling turned out to be a critical determinant of whether cells live or die in response to oxidative stress. Understanding the ACSL4-LPCAT3 partnership provides crucial insight into how cells build the lipid landscape that determines their ferroptosis fate.